Matthew Szot's Securities Transactions in Cadrenal Therapeutics Inc.

Matthew Szot, an officer of Cadrenal Therapeutics Inc., has reported multiple transactions involving the sale of common stock under a 10b5-1 trading plan. The transactions occurred between August 27, 2025, and October 24, 2025, with the largest single transaction involving the sale of 10,900 shares for $153,182.06 on September 25, 2025. The total number of shares sold during this period was 18,000, with aggregate proceeds of $254,442.10. The shares were originally acquired as Founders Shares on May 17, 2022. The transactions were executed through Morgan Stanley Smith Barney LLC Executive Financial Services.